BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goel A, Bhadauria DS, Aggarwal R. Hepatitis C virus infection and chronic renal disease: A review. Indian J Gastroenterol 2018;37:492-503. [PMID: 30560540 DOI: 10.1007/s12664-018-0920-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, Dan YY, Huang CC, Lai CL, Tanwandee T, Teo BW, Wong GL, Yeoh EK, Iseki K, Leung CB, Park HC, Kanjanabuch T, Lu W, Fung J, Jia J, Kanda E, Law MC, Liu H, Loo CK, Mak SK, Lui SL, Tang HL, Wang AY, Yu ML, Cheung M, Jadoul M. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Rep 2020;5:1129-38. [PMID: 32775812 DOI: 10.1016/j.ekir.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Wong XZ, Gan CC, Mohamed R, Yahya R, Ganapathy S, Tan SS, Lim SK. Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients. BMC Nephrol 2020;21:480. [PMID: 33187498 DOI: 10.1186/s12882-020-02154-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Kalita D, Deka S, Chamuah K, Ahmed G. Laboratory Evaluation of Hepatitis C Virus Infection in Patients Undergoing Hemodialysis from North East India. Journal of Clinical and Experimental Hepatology 2022;12:475-82. [DOI: 10.1016/j.jceh.2021.05.011] [Reference Citation Analysis]
4 Wong XZ, Amirah A, Gan CC, Fatiha S, Maznah D, Yahya R, Ganapathy S, Tan SS, Mohamed R, Lim SK. Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. Nephrology (Carlton) 2021;26:463-70. [PMID: 33580732 DOI: 10.1111/nep.13862] [Reference Citation Analysis]
5 Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice . World J Gastroenterol 2022; 28(12): 1226-1238 [DOI: 10.3748/wjg.v28.i12.1226] [Reference Citation Analysis]
6 Zhang J, Liu X, Wu J, Zhou W, Tian J, Guo S, Jia SS, Meng Z, Ni M. A bioinformatics investigation into the pharmacological mechanisms of the effect of the Yinchenhao decoction on hepatitis C based on network pharmacology. BMC Complement Med Ther 2020;20:50. [PMID: 32050950 DOI: 10.1186/s12906-020-2823-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sulkowski M, Telep LE, Colombo M, Durand F, Reddy KR, Lawitz E, Bourlière M, Cheinquer N, Scherbakovsky S, Ni L, Force L, Ramroth H, Gaggar A, Chokkalingam AP, Sise ME. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. Aliment Pharmacol Ther 2022;55:1169-78. [PMID: 35235245 DOI: 10.1111/apt.16830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Goel A, Bhadauria DS, Kaul A, Verma A, Tiwari P, Rungta S, Rai P, Gupta A, Aggarwal R. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant 2021;36:1867-71. [PMID: 33097949 DOI: 10.1093/ndt/gfaa187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hussein NR, Saleema ZSM, Abd QH. Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection. Mediterr J Hematol Infect Dis 2019;11:e2019034. [PMID: 31205638 DOI: 10.4084/MJHID.2019.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]